Pharmacology of testosterone replacement therapy preparations.
Level 5 - mechanism / opinion, no new human data
Narrative review describing pharmacological formulations without systematic search or original data.
PubMed 28078214 · doi:10.21037/tau.2016.07.10
What was done
This narrative review synthesized the pharmacology, pharmacokinetics, delivery routes, and adverse effect profiles of US Food and Drug Administration (FDA)-approved testosterone replacement therapy (TRT) formulations, including buccal, nasal, subdermal, transdermal, and intramuscular preparations.
What was found
No quantitative findings or comparative statistics were reported in the abstract. The abstract identifies multiple approved delivery routes (buccal, nasal, subdermal, transdermal, intramuscular) and notes that optimal formulation selection depends on individual pharmacokinetic differences and patient-specific factors.
Why it matters
It outlines the pharmacological characteristics of various TRT delivery methods to assist clinicians and patients in collaborative treatment selection for hypogonadism.
Limits
The abstract provides no quantitative metrics, effect sizes, or comparative safety data. As a narrative review, it lacks a systematic literature search methodology and does not present original empirical human data.
Cited by
- supports Natesto is an FDA-approved intranasal testosterone spray for testosterone replacement therapy in men.